

OCT 11 2000

1002684

**510(K) SUMMARY OF SAFETY AND EFFECTIVENESS FOR THE COMPOSIX E/X MESH**

**A. Submitter Information**

Submitter's Name: Davol, Inc.  
Address: Subsidiary of C. R. Bard, Inc.  
100 Sockanossett Crossroad  
Cranston, RI 02920  
Telephone: 401-463-7000 ext. 2529  
Fax: 401-463-3845  
Contact Person: Ruth C. Forstadt  
Date of Preparation: August 25, 2000

**B. Device Name**

Composix E/X Mesh

**C. Predicate Device Name**

Trade name: Composix Mesh (Davol Inc.)  
SpermaTex Mesh (Davol Inc.)

**D. Device Description**

The proposed Composix E/X Mesh will be elliptical in shape and manufactured from a single layer of knitted polypropylene monofilament. A single layer of expanded polytetrafluoroethylene (ePTFE) will be attached to this mesh with polytetrafluoroethylene (PTFE) monofilament thread. The peripheral edge of the polypropylene mesh will be heat sealed to the ePTFE layer.

**E. Intended Use**

The Composix E/X Mesh is intended for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias and chest wall defects.

**F. Summary of Similarities and Differences in Technological Characteristics, Performance and Intended Use**

The Composix E/X Mesh and the predicate Composix Mesh have the same intended use, which is for the reconstruction of soft tissue deficiencies, such as the repair of hernias and chest wall defects. The technological characteristics are the same or similar to the predicate

devices in that the materials used to manufacture these products are similar to the predicate polypropylene and ePTFE meshes. Differences include the material used to attach the layers, the shape, the number of layers of mesh, the thickness of the ePTFE layer and the edge design.

**G. Performance Data**

Biocompatibility and bench testing have been completed and support the safety and effectiveness of the Composix E/X Mesh for its intended use. The biocompatibility test results show that the material used in the design and manufacture of the device are non-toxic and non-sensitizing to biological tissues consistent with their intended use.

Laboratory test results demonstrate that the materials chosen and the design utilized in manufacturing the Composix E/X Mesh will meet the established specifications necessary for consistent performance during their intended use.



OCT 11 2000

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Ruth C. Forstadt  
Regulatory Affairs Administration  
Davol, Inc.  
100 Sockanossett Crossroad  
Canston, Rhode Island 02920

Re: K002684  
Trade Name: Composix E/X Mesh  
Regulatory Class: II  
Product Code: FTL  
Dated: August 25, 2000  
Received: August 28, 2000

Dear Ms. Forstadt:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Ms. Ruth C. Forstadt

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "for Mark N. Milburn", is written over the typed name of Celia M. Witten.

Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if known): 1K002684

Device Name: Composix E/X Mesh

Indications for Use: **Reconstruction of soft tissue deficiencies, such as for the repair of hernias and chest wall defects.**

(Please do not write below this line - Continue on another page if needed)

.....  
Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X OR Over-the Counter Use \_\_\_\_\_  
(Per 21 CFR 801.109)

Mash M. Milken  
(Division Sign-Off)

(Optional Format 1-2-96)

Division of General Restorative Devices  
510(k) Number K002684